Structure-based development of a peptidic NOX inhibitor for the treatment of cardiovascular diseases

• Research unit: INNOSUISSE
• Project number: 8024.2;9 LSPP-LS

Short description (English)

Structure-based development of a peptidic NOX inhibitor for the treatment of cardiovascular diseases

Short description (French)

Structure-based development of a peptidic NOX inhibitor for the treatment of cardiovascular diseases

Abstract (French)

GENKYOTEX is a start-up company, coached by the Geneva Biotech incubator Eclosion. GENKYOTEX focuses on the development of NOX inhibitors. Inhibition of oxygen radical-generating NOX enzymes prevents development of cardiovascular diseases (myocardial infarction, aneurysm, hypertension and atherosclerosis). GENKYOTEX capitalizes on more than 20 years of research on NOX enzymes, leading to IP and proprietary cellular and animal models. The objective of this application is the structure based development of a peptide inhibitor of NOX1 and NOX2 as a novel therapeutic agent